Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norgestrel is a synthetic progestin (progestogen) used primarily as an oral contraceptive to prevent pregnancy. It acts mainly by inhibiting ovulation and altering cervical mucus to reduce sperm penetration, thereby preventing fertilization[1][2][4][5]. Norgestrel is available both as a progestin-only pill (Opill, Ovrette) and in combination with estrogens such as ethinylestradiol (as in the combined oral contraceptive brand Ovral)[1][5]. It may also be used in menopausal hormone therapy[5]. Norgestrel is taken orally and does not protect against sexually transmitted infections. Its mechanism of action involves agonism of the progesterone receptor. The drug was patented in 1961 and introduced for medical use in 1966[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norgestrel.